Severe treatment‐resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab

A.-S.H. has no conflicts of interest. C.Z. has received speaker honorarium from CSL, Novartis, and LEO Pharma, and has attended Advisory Boards for AbbVie, CSL, Janssen Cilag, Novartis, Eli Lilly & Co, and LEO Pharma. He has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma, and received research and educational grants from Cellgene and Leo Pharma. J.P.T. has attended advisory boards for Sanofi-Genzyme, Eli Lilly & Co, Pfizer, Abbvie, and Union Therapeutics, and received speaker honorarium from LEO Pharma, Regeneron, Abbvie, and Sanofi-Genzyme, and been an investigator for Sanofi-Genzyme, Eli Lilly & Co, LEO Pharma, Pfizer, and Abbvie.